Immunovant, Inc. (IMVT) is an American clinical stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. The firm specializes in the development of innovative, patient-friendly, subcutaneous therapeutics for autoimmune diseases, a group of conditions that stems from an abnormal immune response to normal body parts. The company has its headquarters in New York City, New York.
Founded as a biopharma venture in December 2019, Immunovant is known for its primary product candidate, IMVT-1401, a novel investigational monoclonal antibody. The therapy is being studied for its potential to be a transformative treatment in a spectrum of autoimmune diseases. It is designed to reduce pathogenic IgG antibodies, which are present at elevated levels in many autoimmune conditions and are often the drivers of disease.
The secret weapon of Immunovant lies in its science. The company focuses on utilizing well-understood biological pathways to create medicines that offer significant improvements over existing treatments and have the potential to offer clinical benefit to a broad population of patients.
This New York-based biotech quickly gained attention in the medical community for its revolutionary approach to treating autoimmune diseases. In their diverse pipeline, IMVT-1401 holds the greatest promise. It is currently under clinical trials for three illnesses - thyroid eye disease, myasthenia gravis, and warm autoimmune hemolytic anemia.
Immunovant, Inc. is free of the pressure to chase blockbuster drugs for massive markets, unlike its larger counterparts. Instead, it is committed to developing and delivering transformative, high-quality therapies for those suffering from autoimmune diseases. While still relatively new to the scene, Immunovant’s dedication to creating innovative solutions needs to be praised. After all, its ultimate goal is to make life significantly better for patients suffering from debilitating diseases and usually overlooked by mainstream drug developers.
Boasting a solid team of experienced scientific, clinical, and corporate professionals, Immunovant is well-equipped to promote research, support development, and make a difference in the autoimmune disease community. The passion they bring to their work and their impact-oriented strategic direction are signs of a robust and future-proof biopharmaceutical company.
Therefore, for anyone closely observing the biotech sector, Immunovant's journey is worth watching. Additional breakthroughs in this field will not only impact this diligent company but also change the lives of many people worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Christopher Van Tuyl, Immunovant's Chief Legal Officer, sold 2,846 shares of company common stock on September 23, 2026. This mandatory sale, at a weighted average price of $36.36 per share, was conducted to cover tax withholding obligations arising from the vesting of 6,872 restricted stock units (RSUs) on September 16, 2026. This transaction was non-discretionary and part of the issuer's "sell to cover" policy, leaving Van Tuyl with 176,545 directly owned shares.
Immunovant (IMVT) shares dropped after its lead drug candidate, IMVT-1402, failed to meet the primary endpoint in a study for cutaneous lupus erythematosus (CLE), leading the company to halt development for this indication. Despite positive trends in some measures, the results did not meet internal thresholds given the competitive landscape. Immunovant will continue to develop IMVT-1402 for other autoimmune diseases and expects its current cash reserves to fund operations through a potential launch in Graves' disease.
Immunovant Inc. (IMVT) announced it is discontinuing the development of IMVT-1402 for cutaneous lupus erythematosus (CLE) after the drug failed to meet its primary endpoint in a proof-of-concept trial. Despite positive safety trends, the company decided to shift focus to other autoimmune conditions due to insufficient clinical outcomes and the competitive landscape. This announcement led to a decline in stock prices for both Immunovant and its parent company, Roivant Sciences Ltd. (ROIV).
Immunovant (NASDAQ: IMVT) is halting its cutaneous lupus development program after its Phase 2b trial for IMVT-1402, or imeroprubart, failed to meet its primary endpoint at Week 12. The study did not show a statistically significant difference in the CLASI-A score, though numerical trends favored treatment. Despite this setback, Immunovant will continue development for five other autoimmune indications, including Graves' disease and myasthenia gravis, with topline results expected in 2027.
Immunovant (NASDAQ: IMVT) discussed its Q1 2027 financial results, reporting a quiet quarter but anticipating a busy second half with several key developments. These include the potential launch of brepocitinib for dermatomyositis, the initiation of a phase 3 study for brepocitinib in cutaneous sarcoidosis, and ongoing litigation. The company maintains a strong financial position with nearly $4 billion in cash and accelerated share repurchases, while strategically focusing on a slow and steady commercial approach for brepocitinib to build a foundation for future expansions.
Immunovant (IMVT) has experienced a recent stock pullback to $37.36, but it still shows a strong 1-year return of 140.6%. While short-term momentum is down, some analyses suggest the stock is undervalued, with a fair value estimate of $48.07, particularly given its pipeline, including IMVT-1402 for Graves' disease. However, its high P/B ratio compared to the biotech sector indicates significant optimism is already priced in, suggesting potential risks if trials disappoint.